---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-066571"
form_type: "8-K"
ticker: "LRMR"
cik: "0001374690"
company_name: "Larimar Therapeutics, Inc."
filed_at: "2024-05-30T23:59:59+00:00"
generated_at: "2026-06-01T07:21:29.375325+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# FDA selects Larimar's nomlabofusp for START pilot program to accelerate FA development

## Summary
- FDA selects nomlabofusp for START pilot program based on potential clinical benefit and program readiness.
- Nomlabofusp is one of three CDER programs selected; BLA submission target remains 2H 2025.
- START program offers enhanced ad-hoc FDA communication to expedite pivotal studies and BLA preparation.
- Interim data from ongoing open-label extension study expected in Q4 2024.
- Nomlabofusp aims to increase frataxin levels, addressing root cause of Friedreich's ataxia.

## SEC filing metadata
- accession: 0000950170-24-066571
- form_type: 8-K
- ticker: LRMR
- cik: 0001374690
- company_name: Larimar Therapeutics, Inc.
- filed_at: 2024-05-30T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374690/000095017024066571/0000950170-24-066571-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374690/000095017024066571/lrmr-20240530.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-066571
- JSON: https://secwatch.observer/filing/0000950170-24-066571.json
- Plain text: https://secwatch.observer/filing/0000950170-24-066571.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.